BridgeBio, Bristol to Develop SHP2 Inhibitor, in Oncology

 BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to $815 million in additional milestone payments and royalties

-SHP2 inhibitor deal expands earlier agreement between BridgeBio and Bristol Myers Squibb to study BBP-398 in combination with OPDIVO® (nivolumab) in advanced solid tumors with KRAS mutations 
  
- BridgeBio will continue to lead its three current Phase 1 monotherapy and BBP-398 combination therapy trials with additional support from Bristol Myers Squibb; future clinical trials will be performed and funded by Bristol Myers Squibb 

https://www.biospace.com/article/releases/bridgebio-announces-exclusive-license-agreement-with-bristol-myers-squibb-to-develop-and-commercialize-bbp-398-a-potentially-best-in-class-shp2-inhibitor-in-oncology/